Klotho Neurosciences has acquired Turn Biotechnologies for an undisclosed amount. The transaction sees Klotho Neurosciences take ownership of Turn Bio's innovative epigenetic reprogramming technologies, which are focused on reversing cellular aging and combating age-related diseases. Turn Biotechnologies has pioneered an advanced methodology, Epigenetic Reprogramming of Age (ERA™), utilizing proprietary mRNA cocktails delivered through cutting-edge systems to restore youthful cell function and address the fundamental hallmarks of aging.
This strategic acquisition significantly enhances Klotho Neurosciences’ capabilities in the burgeoning field of longevity and regenerative medicine. While Klotho Neurosciences’ specific focus is not detailed, the company’s name suggests an emphasis on neurological health and age-related conditions. Integrating Turn Bio’s platform provides Klotho with a powerful tool to explore novel therapeutic approaches for a range of indications where cellular aging plays a critical role, potentially extending into neuroscience applications.
The expected synergies from this acquisition are substantial. Klotho Neurosciences gains immediate access to Turn Bio's scientifically validated ERA™ technology, including its proprietary rejuvenation factors and advanced delivery systems. This integration is anticipated to accelerate research and development initiatives, enabling the combined entity to more effectively target the root causes of age-related cellular decline and dysfunction across various tissues and organs.
Looking ahead, the acquisition positions the combined organization to drive significant advancements in the pursuit of healthy longevity. By uniting Klotho Neurosciences' strategic vision with Turn Biotechnologies' groundbreaking cellular reprogramming platform, the entity aims to bring forward innovative therapies designed to rejuvenate the human body and improve quality of life by directly addressing the biological mechanisms of aging.